CGEM phase III REZILIENT3 reports 14.5-month PFS in EGFR exon 20 NSCLC
Phase III REZILIENT3 trial results are described for zipalertinib plus chemotherapy in first-line EGFR exon 20 NSCLC, including median progression-free survival of 14.5 months and a 50% reduced risk of progression or death.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.